Moderna shares fall after FDA refuses to review new flu vaccine
ReutersFeb 11, 2026 7:27 AM
MILAN, Feb 11 (Reuters) - Moderna MRNA.O shares opened 14% lower in Frankfurt on Wednesday in low volume after the U.S. Food and Drug Administration refused to review the company's approval application for its influenza vaccine.
The company's shares, which closed up 0.1% on Tuesday, are up 42% so far this year.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
5 hours ago
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.TradingKey
6 hours ago
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
19 hours ago
SpaceX IPO Approaching: Will EchoStar Be a Good Buy in 2026?
TradingKey - Today, EchoStar (SATS) is a hybrid story around legacy consumer communications and a high-profile private space play. As a result of its merger with DISH, the company offers satellite TV services and the wireless brand Boost Mobile, in addition to spectrum assets and wholesale network aTradingKey
Tue, Feb 10
